NKTX
Nkarta Inc.
$1.80
+$0.07(+4.05%)
39
Overall
60
Value
18
Tech
--
Quality
Market Cap
$139.21M
Volume
541.79K
52W Range
$1.31 - $3.16
Target Price
$11.80
Company Overview
| Mkt Cap | $139.21M | Price | $1.80 |
| Volume | 541.79K | Change | +4.05% |
| P/E Ratio | -1.3 | Open | $1.72 |
| Revenue | -- | Prev Close | $1.73 |
| Net Income | $-108.8M | 52W Range | $1.31 - $3.16 |
| Div Yield | N/A | Target | $11.80 |
| Overall | 39 | Value | 60 |
| Quality | -- | Technical | 18 |
No chart data available
About Nkarta Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Latest News
Analysts Offer Insights on Healthcare Companies: Rallybio (RLYB) and Nkarta (NKTX)
Brian Anderson•13 days ago
Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NKTX | $1.80 | +4.0% | 541.79K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |